261 related articles for article (PubMed ID: 26985855)
21. Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells.
Grandjenette C; Schnekenburger M; Gaigneaux A; Gérard D; Christov C; Mazumder A; Dicato M; Diederich M
Cancer Lett; 2020 Jan; 469():468-480. PubMed ID: 31734352
[TBL] [Abstract][Full Text] [Related]
22. Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia.
Lei H; Xu HZ; Shan HZ; Liu M; Lu Y; Fang ZX; Jin J; Jing B; Xiao XH; Gao SM; Gao FH; Xia L; Yang L; Liu LG; Wang WW; Liu CX; Tong Y; Wu YZ; Zheng JK; Chen GQ; Zhou L; Wu YL
Nat Commun; 2021 Jan; 12(1):51. PubMed ID: 33397955
[TBL] [Abstract][Full Text] [Related]
23. Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib.
Avilés-Vázquez S; Chávez-González A; Hidalgo-Miranda A; Moreno-Lorenzana D; Arriaga-Pizano L; Sandoval-Esquivel MÁ; Ayala-Sánchez M; Aguilar R; Alfaro-Ruiz L; Mayani H
Cancer Med; 2017 Dec; 6(12):2942-2956. PubMed ID: 29030909
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
25. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
26. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
27. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Liu Z; Li Y; Lv C; Wang L; Song H
Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
[TBL] [Abstract][Full Text] [Related]
28. Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Kayabasi C; Okcanoglu TB; Yelken BO; Asik A; Susluer SY; Avci CB; Saydam G; Gunduz C
Gene; 2017 Dec; 637():173-180. PubMed ID: 28942039
[TBL] [Abstract][Full Text] [Related]
29. Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.
Obr A; Röselová P; Grebeňová D; Kuželová K
PLoS One; 2014; 9(9):e107367. PubMed ID: 25198091
[TBL] [Abstract][Full Text] [Related]
30. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
32. Targeting quiescent leukemic stem cells using second generation autophagy inhibitors.
Baquero P; Dawson A; Mukhopadhyay A; Kuntz EM; Mitchell R; Olivares O; Ianniciello A; Scott MT; Dunn K; Nicastri MC; Winkler JD; Michie AM; Ryan KM; Halsey C; Gottlieb E; Keaney EP; Murphy LO; Amaravadi RK; Holyoake TL; Helgason GV
Leukemia; 2019 Apr; 33(4):981-994. PubMed ID: 30185934
[TBL] [Abstract][Full Text] [Related]
33. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
34. Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling.
Li Y; Hu J; Song H; Wu T
Biochem Biophys Res Commun; 2018 Nov; 505(3):858-864. PubMed ID: 30301525
[TBL] [Abstract][Full Text] [Related]
35. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Pungolino E; D'adda M; De Canal G; Trojani A; Perego A; Elena C; Lunghi F; Turrini M; Borin L; Iurlo A; Latargia ML; Carraro MC; Spina F; Artale S; Anghilieri M; Molteni A; Caramella M; Baruzzo G; Nichelatti M; Di Camillo B; Cairoli R
Eur J Haematol; 2021 Oct; 107(4):436-448. PubMed ID: 34139044
[TBL] [Abstract][Full Text] [Related]
36. Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
Chiarenza A; Manetti F; Petricci E; Ruat M; Naldini A; Taddei M; Carraro F
PLoS One; 2016; 11(3):e0149919. PubMed ID: 26934052
[TBL] [Abstract][Full Text] [Related]
37. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
38. Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells.
Tusa I; Cheloni G; Poteti M; Gozzini A; DeSouza NH; Shan Y; Deng X; Gray NS; Li S; Rovida E; Dello Sbarba P
Stem Cell Reports; 2018 Oct; 11(4):929-943. PubMed ID: 30245209
[TBL] [Abstract][Full Text] [Related]
39. Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.
Woywod C; Gruber FX; Engh RA; Flå T
PLoS One; 2017; 12(7):e0179700. PubMed ID: 28678800
[TBL] [Abstract][Full Text] [Related]
40. Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
Agarwal P; Zhang B; Ho Y; Cook A; Li L; Mikhail FM; Wang Y; McLaughlin ME; Bhatia R
Blood; 2017 Feb; 129(8):1008-1020. PubMed ID: 28011678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
